Dr Sumit Gupta (University of Toronto, Canada) and colleagues investigated 24,979 patients with ALL, ranging from 0–31 years of age, who were enrolled in COG frontline ALL trials between 2004 and 2019, to study health outcomes across race, ethnicity, SES, and disease prognosticators. SES was inferred by insurance status. The main outcomes were event-free survival (EFS) and overall survival (OS). Change in estimate approach was used to evaluate the relative contribution of race, ethnicity, SES, and disease prognosticators.
The 5-year EFS rates among White (87.4%) and Asian patients (88.1%) was higher than the 5-year EFS rates among Hispanic (82.8%) and Black patients (81.9%). Furthermore, the EFS rate was higher in patients with non-US insurance (89.0%) or private insurance (86.3%) compared with patients who received federal support for healthcare costs via US Medicaid (83.2%).
In addition, change in estimate analysis revealed that the reported disparities could not be fully explained by disease prognosticators or leukaemia biology. In Hispanic patients, the hazard ratio for EFS changed from 1.37 to 1.11 when adjusting for SES and disease prognosticators, demonstrating a significant influence of these factors. In Black patients, the hazard ratio changed from 1.45 to 1.32 after adjustment, leaving a significant proportion of the increased risk in this subgroup unexplained by adjustment. Dr Gupta added that the observed disparities in OS were wider, indicating that access to relapse care may be insufficient in various subgroups. Notably, additional analysis showed that the results were significant in patients with B-lineage disease phenotype (P<0.001) but not in patients with T-lineage disease phenotype (P=0.47).
Dr Gupta argued that future studies should investigate access to care, quality of care, and institutional racism to explain the reported disparities.
- Gupta S, et al. Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children’s Oncology Group (COG) Study. Abstract 211, ASH 2021 Annual Meeting, 11–14 December.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL Next Article
New Interfant protocol includes blinatumomab for KMT2A-r ALL »
« EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL Next Article
New Interfant protocol includes blinatumomab for KMT2A-r ALL »
Table of Contents: ASH 2021
Featured articles
Acute Lymphoblastic Leukaemia
New Interfant protocol includes blinatumomab for KMT2A-r ALL
Persistent disparities in ALL health outcomes
EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL
UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL
Acute Myeloid Leukaemia
AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML
Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients
Promising frontline triplet regimen for TP53-mutated AML
Encouraging results of novel triplet combination for AML
Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
Benefits of eprenetapopt plus azacitidine for TP53-mutant MDS and oligoblastic AML
Improved risk stratification in MDS via gene-based scoring system
Chronic Leukaemia
CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL
SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL
Investigational therapies superior to standard-of-care in double-exposed CLL
Multiple Myeloma
GRIFFIN: Sustained responses of daratumumab plus RVd in MM
MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM
iStopMM: Smouldering MM highly prevalent in general population
Mechanisms of D-KRd treatment failure in MM identified
TRIMM-2: Favourable results of talquetamab plus daratumumab for MM
Lymphoma
Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma
Axi-cel improved event-free survival in R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in DLBCL
POLARIX: Novel regimen superior to R-CHOP in DLBCL
Novel non-invasive biomarker ctDNA shows value in CNS lymphoma
Myeloproliferative Neoplasms
Mechanisms behind TP53 mutations revealed in myeloproliferative neoplasms
JAK2V617F variant allele frequency prognostic of venous events in polycythaemia vera
Immune Thrombocytopenia
Promising results of tacrolimus plus dexamethasone for ITP
Sustained remission after TPO-RA discontinuation in chronic ITP
Haemophilia
Fitusiran meets primary endpoint in ATLAS-A/B trial
ATLAS-INH: Impressive results of fitusiran for haemophilia with inhibitors
rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors
Clonal Haematopoiesis
Reduced risk of Alzheimer’s disease in CHIP carriers
Lifelong patterns of clonal haematopoiesis revealed
Related Articles
February 4, 2022
Reduced risk of Alzheimer’s disease in CHIP carriers
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com